

Dicerna's hyperoxaluria treatment gets orphan status from FDA

18 May 2018 | News

The FDA granted the status to Dicerna's synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues.



Singapore- Dicerna Pharmaceutical's drug recently received an orphan drug status designation for its treatment for primary hyperoxaluria.

The FDA granted the status to Dicerna's synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues.

Dicerna is working to improve the lives of people suffering from diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its proprietary, next-generation technology, known as RNA interference or RNAi, uses the body's natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity.